Enterin
Philadelphia-based biotechnology company improving the quality of life of patients with neurodegenerative conditions by repairing the gut-brain axis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $5.1m Valuation: $71.0m | Series D |
| Total Funding | 000k | ||
Related Content
Enterin Inc. is a pioneering biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases by targeting the gut-brain axis. The company operates in the healthcare and pharmaceutical market, primarily serving patients with conditions such as Parkinson's Disease. Enterin's business model revolves around the research and development of novel drugs, with its lead compound, ENT-01, currently in Phase 2B clinical trials. The company generates revenue through the development and potential commercialization of its proprietary treatments. By restoring normal signaling between the gut and the brain, Enterin aims to significantly improve the quality of life for patients suffering from neurodegenerative diseases.
Keywords: biopharmaceutical, neurodegenerative, gut-brain axis, Parkinson's, ENT-01, clinical trials, drug development, healthcare, innovation, quality of life.